Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

also called a Zepbound pen. The vial doses available are 2.5 mg and 5 mg, which is limited compared to the six Zepbound pen doses. Single-dose vials may be less convenient than an auto-injector pen.

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

Zepbound is a GLP-1 agonist containing tirzepatide ... and 3.2% (with diabetes). Starting dose: 2.5 mg weekly, increasing to 5 mg after 4 weeks. Doses may continue to increase to a maximum ...

Eli Lilly has launched new single-dose 2.5mg and 5.0mg vials of its obesity drug Zepbound in a move that it said would make it easier for people paying for the drug out-of-pocket to afford treatment.

Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% jump in the Danish drugmaker’s share price in premarket trading.